The effect of the response to the coronavirus dis-ease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Ka-Won | - |
dc.contributor.author | Lee, Byung-Hyun | - |
dc.contributor.author | Jeon, Min Ji | - |
dc.contributor.author | Yu, Eun Sang | - |
dc.contributor.author | Kim, Dae Sik | - |
dc.contributor.author | Lee, Se Ryeon | - |
dc.contributor.author | Sung, Hwa Jung | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.date.accessioned | 2022-02-15T05:42:13Z | - |
dc.date.available | 2022-02-15T05:42:13Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/135827 | - |
dc.description.abstract | Background/Aims:Relatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment out-comes in this patient population. Methods: We retrospectively analyzed data on patients treated for lymphoma or multiple myeloma in two tertiary hospitals in Seoul. Patients were divided into two groups: group 1 included patients who received chemotherapy between Sep-tember and December 2019 (the control period), and group 2 included patients who received chemotherapy between September and December 2020 (the study period). Countermeasures to COVID-19 were applied to the patients in group 2. The countermeasures implemented included mask wearing and regular hand-washing at home and in hospital; COVID-19 risk assessments on all hospital visi-tors; and pre-emptive COVID-19 screening for all newly hospitalized patients and their resident guardians. Results: No differences in treatment outcomes, including treatment response, incidence and duration of neutropenia or neutropenic fever, delays in chemo-therapy, or number of deaths during chemotherapy, were observed between the g roups. None of the patients in group 2 tested positive for COVID-19, and there were no COVID-19-related deaths during the study period. Conclusions: Countermeasures to COVID-19 did not affect treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. Data on the effect of countermeasures to COVID-19 on treatment outcomes should continue to be analyzed to ensure that treatment outcomes are not adversely affected. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | DISEASE 2019 | - |
dc.subject | COVID-19 | - |
dc.subject | PREVENTION | - |
dc.subject | CANCER | - |
dc.subject | TRANSMISSION | - |
dc.subject | INFECTION | - |
dc.subject | MORTALITY | - |
dc.subject | CRITERIA | - |
dc.title | The effect of the response to the coronavirus dis-ease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.identifier.doi | 10.3904/kjim.2021.186 | - |
dc.identifier.scopusid | 2-s2.0-85120824444 | - |
dc.identifier.wosid | 000723847800001 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.36, no.6, pp.1459 - + | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 36 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1459 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002768192 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | CRITERIA | - |
dc.subject.keywordPlus | DISEASE 2019 | - |
dc.subject.keywordPlus | COVID-19 | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TRANSMISSION | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordAuthor | Treatment outcome | - |
dc.subject.keywordAuthor | Lymphoma | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Coronavirus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.